Dartmouth’s Geisel School of Medicine and the Dartmouth Institute for Health Policy & Clinical Practice has become the first US academic center to sign up for the AllTrials campaign, and will take the lead in urging all medical schools and patient advocacy groups in the US to add their voices at AllTrials.net.
At the launch of the campaign in the US, the National Breast Cancer Coalition (NBCC) joined Dartmouth’s call for patients, researchers and physicians to join. NBCC is the grassroots advocacy organization that seeks to improve public policies surrounding breast cancer research, diagnosis and treatment. NBCC said today that patients who have participated in clinical trials expect findings generated by their participation to be shared with researchers to advance the field.
The AllTrials campaign, which calls for all clinical trials to be registered and results reported, was launched in the United Kingdom in January 2013. Some 48,000 people and more than 250 organizations, including more than 100 patient advocacy groups, have joined. In February 2013, GSK became the first pharmaceutical company to join the campaign.